{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/analgesia-mild-to-moderate-pain/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 824c65b7-d4eb-42f9-a7e5-93abe37592f2 --><h2>Changes</h2><!-- end field 824c65b7-d4eb-42f9-a7e5-93abe37592f2 -->","summary":null,"htmlStringContent":"<!-- begin item 08a843bc-3a42-43b1-a598-f8d94b3e3b16 --><!-- begin field 71f1f9bb-e3eb-4aa3-91e0-de2c6b838197 --><p><strong>August 2020</strong> — reviewed. A literature search was conducted in July 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations. </p><!-- end field 71f1f9bb-e3eb-4aa3-91e0-de2c6b838197 --><!-- end item 08a843bc-3a42-43b1-a598-f8d94b3e3b16 -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","lastRevised":"Last revised in August 2020","chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","fullItemName":"Management","slug":"management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c3588f2a-494e-54f0-9e5a-ee2bba7117ce","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 8652871b-ff10-4780-9810-84253a3a3bc0 --><h3>Previous changes</h3><!-- end field 8652871b-ff10-4780-9810-84253a3a3bc0 -->","summary":null,"htmlStringContent":"<!-- begin item 2e6c8718-aeaf-4e72-bf07-f26966dd21fa --><!-- begin field 53004e5b-650e-4841-93e3-9b7b8b289204 --><p><strong>July to September 2015</strong> — reviewed. A literature search was conducted in July 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations. Prescribing information on nonsteroidal anti-inflammatory drugs (NSAIDs) has been removed as there is a separate CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</p><p><strong>April 2015</strong> — minor update. Update to the text to reflect a new law on drugs and impaired driving.</p><p><strong>June 2014</strong> — minor update. Update to the text to reflect the fact that tramadol has been reclassified to a schedule 3 controlled drug.</p><p><strong>March 2014</strong> — minor update. Update to the text to remove diclofenac as a drug option. Naproxen and ibuprofen are associated with a lower risk of gastrointestinal and cardiovascular adverse effects.</p><p><strong>February 2014</strong> — minor update. Update to the text of adverse effects of weak opioids. Tramadol is now known to cause hypoglycaemia (frequency unknown).</p><p><strong>January 2014</strong> — minor update. The text regarding the use of codeine during breastfeeding has been updated to reflect new guidance from the Medicines and Healthcare products Regulatory Agency (MHRA). Codeine is no longer recommended for breastfeeding mothers, and tramadol and dihydrocodeine are preferred alternatives.</p><p><strong>December 2013</strong> — minor update. The link to the UK Medicines Information (UKMi) drugs in lactation website has been removed as this no longer exists.</p><p><strong>July 2013</strong> — minor update. Update to the text to reflect the European Medicines Agency (EMA) warning, which now restricts the use of codeine in children and adolescents. Update to the text to reflect recent advice from the MHRA regarding diclofenac. Update to the text to reflect new guidance issued by the National Institute for Health and Care Excellence (NICE) for feverish illness in children.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011</strong> — minor update. More exact paracetamol dosing for children has been introduced by the MHRA. Text and prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011</strong> — minor update. Text updated to include more detailed advice on the use of paracetamol in pregnancy. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>January 2011</strong> — minor update. Prescriptions for analgesics added. Issued in February 2011.</p><p><strong>April to August 2010</strong> — this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified.</p><!-- end field 53004e5b-650e-4841-93e3-9b7b8b289204 --><!-- end item 2e6c8718-aeaf-4e72-bf07-f26966dd21fa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}